PARP Inhibitors Explained 💊🧬 : BRCA, Synthetic Lethality, MOA & Landmark Trials | FRCR Oncology

In this comprehensive lecture, I explain: ✅ DNA damage and repair pathways (PARP & BRCA1/2) ✅ Mechanism of action of PARP inhibitors ✅ Synthetic lethality in BRCA-deficient cancers ✅ Why normal cells are relatively spared ✅ SOLO-1, PAOLA-1, PRIMA, OlympiA, OlympiAD, EMBRACA, POLO, PROfound, TRITON-2, PROPEL, MAGNITUDE & TALAPRO trials ✅ Indications, dosages, toxicities, and mechanism of resistance In this comprehensive lecture, I simplify the concept of PARP inhibitors from basic molecular biology to evidence-based clinical oncology. This video is designed for Radiation Oncology residents, Medical Oncology trainees, FRCR/FCPS/MD/IMM candidates, and medical students who want a strong conceptual foundation as well as exam-oriented clinical knowledge. 📚 What You'll Learn: 🧬 DNA Damage & Repair ✔️ How DNA damage occurs by endogenous and exogenous agents ✔️ Single-strand breaks (SSBs) vs Double-strand breaks (DSBs) ✔️ PARP-mediated repair pathway for SSBs ✔️ BRCA1/BRCA2 homologous recombination repair (HRR) pathway for DSBs 🎯 Mechanism of Action of PARP Inhibitors ✔️ How PARP inhibitors work ✔️ PARP trapping ✔️ Accumulation of DNA damage ✔️ Cancer cell death 🧩 Synthetic Lethality Explained ✔️ What is synthetic lethality? ✔️ Why BRCA-deficient cancer cells die after PARP inhibition ✔️ Why normal cells are relatively spared 💊 PARP Inhibitors Covered • Olaparib • Niraparib • Rucaparib • Talazoparib 📊 Landmark Clinical Trials 🎗️ Ovarian Cancer ✔️ SOLO-1 ✔️ PAOLA-1 ✔️ PRIMA • Key eligibility criteria • Major findings • Median Progression-Free Survival (mPFS) 🎗️ Breast Cancer ✔️ OlympiA ✔️ OlympiAD ✔️ EMBRACA • Key eligibility criteria • Major findings 🎗️ Pancreatic Cancer ✔️ POLO Trial • Key eligibility criteria • Major findings 🎗️ Prostate Cancer ✔️ PROfound ✔️ TRITON-2 ✔️ PROPEL ✔️ MAGNITUDE ✔️ TALAPRO studies • Key eligibility criteria • Major findings 🏥 Clinical Practice ✔️ Approved indications ✔️ Patient selection ✔️ Drug dosages ✔️ Common toxicities ✔️ Monitoring ✔️ Mechanisms of resistance 🎓 Perfect for: FRCR • IMM • FCPS • MD Oncology • Radiation Oncology Boards • Medical Oncology • DM Oncology • Medical Students Master CDK4/6 inhibitors in under 12 minutes    • Master CDK4/6 inhibitors in under 12 minut...   Anti-Androgens in Prostate Cancer    • Anti-Androgens in Prostate Cancer | Bicalu...   Prodige-23 and related biostatistics: RMST, DFS, RCT's and Trial Phases    • 📊 📈 RCT, DFS, RMST & Trials Phases Explain...   RT indications in breast carcinoma    • 🎓 Radiotherapy in Breast Cancer | Basics o...   ⏱️ Chapters 00:00 Introduction 01:15 How PARP enzyme works? 02:00 PARPi and BRCA proficient cell 03:31 What is synthetic lethality? 04:23 Normal cells are not affected by PARPi 05:57 Ovarian Cancer Trials 07:02 Breast Cancer Trials 08:37 Pancreatic Cancer Trial 09:08 Prostate Cancer Trials 10:30 Indications 11:11 Toxicities 12:14 Dosage 13:12 Resistance Mechanisms 13:43 Summary 📌 If you found this lecture helpful, please Like, Share, and Subscribe to OncoWithAsad for evidence-based oncology lectures, clinical trial discussions, FRCR preparation, and practical radiation oncology teaching. #PARPInhibitors #Olaparib #Niraparib #Rucaparib #Talazoparib #SyntheticLethality #BRCA #DNARepair #OvarianCancer #BreastCancer #ProstateCancer #PancreaticCancer #FRCR #FCPS #RadiationOncology #MedicalOncology #ClinicalTrials #OncoWithAsad #OncologyEducation #MedicalEducation